Cancer Discovery (journal)

The study team included, from left, Paula Gonzalez-Ericsson, MD, Xiaopeng Sun, Justin Balko, PharmD, PhD, and Brandie Taylor, MS. (photo by Donn Jones)
October 4, 2023

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

By Tom Wilemon
May 11, 2023

Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.

By Tom Wilemon
July 28, 2022

C. difficile may contribute to colorectal cancer: study

A Vanderbilt study found that the bacterium Clostridioides difficile (C. difficile) may be a previously unrecognized contributor to colorectal cancer.

By Bill Snyder
December 22, 2020

Arthritis drug may treat immunotherapy-related heart complication

By Tom Wilemon
July 22, 2020

New data offer insights on COVID treatments for people with cancer

Newly released data on treatment outcomes of people with cancer diagnosed with COVID-19 reveal a racial disparity in access to Remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite effect in the general patient population.

By Tom Wilemon
red three darts arrows in the target center
August 3, 2017

Investigators match novel cancer mutations with potential therapies

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.

By VUMC News and Communications
November 21, 2013

Therapeutic target for synovial sarcoma

Inhibitors of a signaling pathway that is critical to synovial sarcoma tumorigenesis may be useful treatments for this aggressive cancer.
By Leigh MacMillan
September 21, 2012

HER2 may impact lung cancer therapy

A protein associated with aggressive breast cancers may also influence resistance of lung cancer to targeted therapies.
By VUMC News and Communications